2010-08-27 17:18:07 -
Research and Markets ( www.researchandmarkets.com/research/db0b08/type_2_diabetes : 
) has announced the addition of GlobalData 's new report " Type 2 Diabetes - Pipeline Assessment and Market Forecasts to 2017 : " to their offering.
Type 2 Diabetes - Pipeline Assessment and Market Forecasts to 2017 is an essential source of information and analysis on the global type 2 diabetes therapeutics market. The report identifies the key trends shaping and driving the global type 2 diabetes therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the market positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global type 2 diabetes sector.
This
report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.
The authors estimated the type 2 diabetes market to be worth $21.9 billion in 2009. The market is forecast to reach $36.1 billion by 2017 with a Compound Annual Growth Rate (CAGR) of 6% between 2010 and 2017.
The main factors driving the growth of the market are the rapid growth in prevalence rates in the UK and the US, an increase in the utilization of premium priced drugs such as glitazones, an increase in prescriptions for combination drugs and an increase in the prevalence of obesity.
Studies have found that obese people are three times more likely to be diagnosed with diabetes than normal people. The type 2 diabetes market has unmet needs in terms of safety and patient compliance. These unmet needs imply that the market is moderately served by the current treatment options and that significant potential exists for new entrants targeting these unmet needs.
The authors analysis reveals that there are over 251 molecules in various stages of the pipeline. Victoza, one of the promising drugs, is awaiting the US Food and Drug Administrations (FDA) approval. The drug was approved by the European Medicines Agency (EMEA) in 2009. The late stage pipeline includes a few first-in-class and promising drugs such as dapagliflozin and D-Tagatose. These molecules differ from others as their site of action is different from that of the already marketed products. The major new classes of drugs include SGLT-2 inhibitors, 11 HSD inhibitors, CCR2 antagonists, selective inhibitors of fructose 1,6-bisphosphatase, immune modulators, cortisol synthesis inhibitors, interleukin-1 antagonists, Gastrin-Releasing Peptide (GRP) receptor agonists, GPR 119 agonists, TLR-4 receptor agonists, FXR antagonists and antisense drugs targeting glucagon receptors. Scope
The scope of the report includes.
- Annualized global type 2 diabetes therapeutics market revenue data from 2001 to 2009, forecast for eight years to 2017.
- Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include SGLT-2 inhibitors, 11 HSD inhibitors, CCR2 antagonists, selective inhibitors of fructose 1,6-bisphosphatase, immune modulators, cortisol synthesis inhibitors, interleukin-1 antagonists, Gastrin-Releasing Peptide (GRP) receptor agonists, GPR 119 agonists, TLR-4 receptor agonists, FXR antagonists and antisense drugs targeting glucagon receptors.
- Analysis of the current and future market competition in the global type 2 diabetes therapeutics market. The key future market players covered are F. Hoffmann-La Roche, Novo Nordisk, Merck & Co., Novartis AG, Sanofi-aventis, Eli Lilly and Company and GlaxoSmithKline.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include a strategic competitor assessment, a market characterization, the unmet needs and the implications for the type-2 diabetes market
Reasons to buy
The report will enhance your decision making capability. It will allow you to.
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global type 2 diabetes therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to affect the global type 2 diabetes therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidation, investments and strategic partnerships.
- What's the next big thing in the global type 2 diabetes therapeutics market landscape? - Identify, understand and capitalize.
Key Topics Covered:
1 Table of contents
2 Diabetes Therapeutics Market: Introduction
3 Type 2 Diabetes Therapeutics: Market Characterization
4 Type 2 Diabetes Therapeutics Market: Competitive Assessment
5 Type 2 Diabetes Therapeutics Market: Pipeline Assessment
6 Type 2 Diabetes Therapeutics Market: Implications for Future Market Competition
7 Type 2 Diabetes Therapeutics Market: Future Players in the Type 2 Diabetes Market
8 Type 2 Diabetes Therapeutics Market: Appendix
Companies Mentioned.
- GlaxoSmithKline
- Hoffmann-La Roche
- Novo Nordisk
- Merck & Co., Inc.
- Novartis AG
- Sanofi-aventis
- Eli Lilly and Company
For more information visit
www.researchandmarkets.com/research/db0b08/type_2_diabetes :
Research and MarketsLaura Wood, Senior Manager
press@researchandmarkets.com : mailto:press@researchandmarkets.com U.S.
Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716
